dievini Hopp BioTech holding GmbH & Co. KG, often referred to simply as dievini, is a German family office and venture capital investment firm. The firm focuses its investments on companies within the life and health sciences sectors, with a particular emphasis on innovative therapeutic and diagnostic procedures. Their goal is to support the development of novel treatment forms that offer significantly improved efficacy and tolerability for patients, especially in life-threatening indications such as oncology, neurology, and infectiology. dievini also invests in companies pursuing unique and first-in-class diagnostic and therapeutic approaches, including those in personalized medicine and cell therapy.dievini was founded in 2005 by the family of Dietmar Hopp, the co-founder of SAP. The firm was established to manage Dietmar Hopp's biotechnology portfolio and has since grown to become an active investor in the European life sciences landscape. Key figures in the firm's formation include Christof Hettich and Friedrich Bohlen. The firm's long-term financial commitment underscores its dedication to fostering groundbreaking advancements in healthcare.The firm's portfolio includes notable investments in companies such as CureVac, a biopharmaceutical company developing mRNA-based drugs, and Apogenix, which focuses on innovative protein therapeutics for the treatment of cancer and other diseases. Other investments include Heidelberg Pharma AG and AaviGen GmbH. dievini typically invests in later-stage venture rounds, including Series C, Series D, and growth stages, providing substantial capital to support the global development and commercialization efforts of its portfolio companies.The management team at dievini supports its portfolio companies in their corporate and business development. Dr. Mathias Hothum serves as a key member of the management team and as a Managing Director, bringing expertise to guide the firm's investment strategy and portfolio oversight. The firm's geographic investment focus is primarily on Germany and Europe, with investments extending to countries like Switzerland and Italy, reflecting its commitment to the European biotechnology ecosystem.
